SHIGETECVAX 5th Annual Meeting held on 19 November 2025

The SHIGETECVAX consortium successfully convened its 5th Annual Meeting on 19 November 2025. Participants from Austria (Eveliqure), Bangladesh (icddr,b), Germany (European Vaccine Initiative, EVI), Sweden (University of Gothenburg, UGOT), and the USA (PATH) gathered virtually to review progress and align on next steps in the development of a novel vaccine to protect against Shigella/ETEC infection. The consortium continues to be guided by the expertise and strategic oversight of the SHIGETECVAX Scientific and Ethics Advisory Committee.

A key highlight of this year’s meeting was the near completion of the Phase 1b age-descending clinical trial in Bangladesh. Immunological analyses are now underway. The consortium will focus next on finalising data cleaning, analysis, and reporting in preparation for upcoming regulatory and programmatic milestones.

In parallel, substantial progress has been achieved on the formulation development workstream. A lead and back-up heat-stable, fast-dissolving formulation of the vaccine candidate have been successfully identified, an important step towards facilitating vaccine use in low-resource settings.

The SHIGETECVAX partners remain committed to advancing this innovative oral vaccine candidate and addressing the global burden of Shigella and ETEC infections.